Stefan Oschmann, Merck KGaA CEO (Sipa USA via AP Images)

Mer­ck KGaA ex­pands its deal with Pfiz­er/BioN­Tech with an eye on a key vac­cine man­u­fac­tur­ing bot­tle­neck

As Pfiz­er and BioN­Tech’s vac­cine de­liv­ery runs be­hind sched­ule in the EU, Mer­ck KGaA is aim­ing to boost pro­duc­tion by ac­cel­er­at­ing its sup­ply of cus­tom lipids to BioN­Tech.

The Darm­stadt, Ger­many-based biotech has promised to ex­pand its pro­duc­tion of lipids, which are crit­i­cal in get­ting the mR­NA tech­nol­o­gy in­to the body. Com­pli­cat­ing mat­ters fur­ther is that on­ly a se­lect few man­u­fac­tur­ers are cur­rent­ly equipped to man­u­fac­ture the lipids in stan­dards con­sis­tent enough for vac­cine pro­duc­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.